131 related articles for article (PubMed ID: 21137077)
1. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients.
Carlsson A; Persson O; Ingvarsson J; Widegren B; Salford L; Borrebaeck CA; Wingren C
Proteomics Clin Appl; 2010 Jul; 4(6-7):591-602. PubMed ID: 21137077
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
3. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
[TBL] [Abstract][Full Text] [Related]
4. Serum GFAP is a diagnostic marker for glioblastoma multiforme.
Jung CS; Foerch C; Schänzer A; Heck A; Plate KH; Seifert V; Steinmetz H; Raabe A; Sitzer M
Brain; 2007 Dec; 130(Pt 12):3336-41. PubMed ID: 17998256
[TBL] [Abstract][Full Text] [Related]
5. Immunotreatment in patients with glioblastoma multiforme--a histopathological evaluation of reactive and inflammatory changes.
Persson A; Skagerberg G; Salford LG; Englund E;
Clin Neuropathol; 2005; 24(5):201-8. PubMed ID: 16167543
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century.
Chaudhry NS; Shah AH; Ferraro N; Snelling BM; Bregy A; Madhavan K; Komotar RJ
Cancer Invest; 2013 Jun; 31(5):287-308. PubMed ID: 23614654
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
Wang LF; Fokas E; Bieker M; Rose F; Rexin P; Zhu Y; Pagenstecher A; Engenhart-Cabillic R; An HX
Oncol Rep; 2008 Jan; 19(1):151-6. PubMed ID: 18097589
[TBL] [Abstract][Full Text] [Related]
8. Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology.
Necesalová E; Vranová V; Kuglík P; Cejpek P; Jarosová M; Pesáková M; Relichová J; Veselská R
Neoplasma; 2007; 54(3):212-8. PubMed ID: 17447852
[TBL] [Abstract][Full Text] [Related]
9. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments.
Kesari S
Semin Oncol; 2011 Dec; 38 Suppl 4():S2-10. PubMed ID: 22078644
[TBL] [Abstract][Full Text] [Related]
10. Towards developing biomarkers for glioblastoma multiforme: a proteomics view.
Jayaram S; Gupta MK; Polisetty RV; Cho WC; Sirdeshmukh R
Expert Rev Proteomics; 2014 Oct; 11(5):621-39. PubMed ID: 25115191
[TBL] [Abstract][Full Text] [Related]
11. APRIL is increased in serum of patients with brain glioblastoma multiforme.
Iłzecka J; Iłzecki M
Eur Cytokine Netw; 2006 Dec; 17(4):276-80. PubMed ID: 17353162
[TBL] [Abstract][Full Text] [Related]
12. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.
Reddy SP; Britto R; Vinnakota K; Aparna H; Sreepathi HK; Thota B; Kumari A; Shilpa BM; Vrinda M; Umesh S; Samuel C; Shetty M; Tandon A; Pandey P; Hegde S; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Kondaiah P; Somasundaram K; Rao MR
Clin Cancer Res; 2008 May; 14(10):2978-87. PubMed ID: 18483363
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
14. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Debinski W; Gibo DM; Hulet SW; Connor JR; Gillespie GY
Clin Cancer Res; 1999 May; 5(5):985-90. PubMed ID: 10353730
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma multiforme in skin: a report of 2 cases and review of the literature.
Mentrikoski M; Johnson MD; Korones DN; Scott GA
Am J Dermatopathol; 2008 Aug; 30(4):381-4. PubMed ID: 18645311
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
Chiba Y; Hashimoto N; Tsuboi A; Rabo C; Oka Y; Kinoshita M; Kagawa N; Oji Y; Sugiyama H; Yoshimine T
Brain Tumor Pathol; 2010 Apr; 27(1):29-34. PubMed ID: 20425045
[TBL] [Abstract][Full Text] [Related]
18. Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin.
Yokota T; Kouno J; Adachi K; Takahashi H; Teramoto A; Matsumoto K; Sugisaki Y; Onda M; Tsunoda T
Acta Neuropathol; 2006 Jan; 111(1):29-38. PubMed ID: 16320026
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma multiforme: evidence-based approach to therapy.
Nicholas MK
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S23-7. PubMed ID: 18076314
[TBL] [Abstract][Full Text] [Related]
20. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
